Tags

Type your tag names separated by a space and hit enter

[Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas].
Dtsch Med Wochenschr. 1995 Jun 09; 120(23):821-5.DM

Abstract

More than 90% of tumours of the pancreas have mutations on codon 12 of the Ki-ras oncogene. Cellular DNA from pancreatic secretions and fine-needle biopsies, obtained from 69 patients (41 men, 28 women), were amplified by the polymerase chain reaction (PCR) to demonstrate this characteristic marker. All these patients had undergone endoscopic retrograde pancreatography for suspected pancreatitis or carcinoma of the pancreas. Two different methods were developed to demonstrate the mutations. With the aid of one of these methods, enrichment PCR with analysis of the restriction fragment length (FL), mutations on codon 12 of the Ki-ras gene were demonstrated in unstimulated pancreatic secretions of 29 of 33 patients with pancreatic carcinoma. All eleven fine-needle biopsies that had been cytologically examined showed the tumour-specific mutation. After direct sequencing of enrichment PCR a codon 12 mutation was demonstrated in pancreatic secretion from 21 of 24 patients and with the single strand conformation polymorphism analysis in 17 of 33 patients. In two of these 33 patients two different Ki-ras mutations were discovered. No mutations were found in acute inflammations or stone disease, while in five patients with chronic pancreatitis mutations were demonstrated only in those two patients in whom histological examination had revealed precancerous mucinous hyperplasia. This investigation indicates that codon 12 mutations of the Ki-ras gene, found after PCR in pancreatic secretion and biopsies, constitute a sensitive and specific tumour marker whose clinical value is being assessed.

Authors+Show Affiliations

Medizinische Kliniken I und II, Universität des Saarlandes, Homburg/Saar.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

ger

PubMed ID

7781522

Citation

Daus, H, et al. "[Ki-ras Mutation as a Molecular Tumor Marker for Carcinoma of the Pancreas]." Deutsche Medizinische Wochenschrift (1946), vol. 120, no. 23, 1995, pp. 821-5.
Daus H, Trümper L, Bürger B, et al. [Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas]. Dtsch Med Wochenschr. 1995;120(23):821-5.
Daus, H., Trümper, L., Bürger, B., Jacobs, G., Kriener, S., von Blohn, G., Zeitz, M., & Pfreundschuh, M. (1995). [Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas]. Deutsche Medizinische Wochenschrift (1946), 120(23), 821-5.
Daus H, et al. [Ki-ras Mutation as a Molecular Tumor Marker for Carcinoma of the Pancreas]. Dtsch Med Wochenschr. 1995 Jun 9;120(23):821-5. PubMed PMID: 7781522.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas]. AU - Daus,H, AU - Trümper,L, AU - Bürger,B, AU - Jacobs,G, AU - Kriener,S, AU - von Blohn,G, AU - Zeitz,M, AU - Pfreundschuh,M, PY - 1995/6/9/pubmed PY - 1995/6/9/medline PY - 1995/6/9/entrez SP - 821 EP - 5 JF - Deutsche medizinische Wochenschrift (1946) JO - Dtsch Med Wochenschr VL - 120 IS - 23 N2 - More than 90% of tumours of the pancreas have mutations on codon 12 of the Ki-ras oncogene. Cellular DNA from pancreatic secretions and fine-needle biopsies, obtained from 69 patients (41 men, 28 women), were amplified by the polymerase chain reaction (PCR) to demonstrate this characteristic marker. All these patients had undergone endoscopic retrograde pancreatography for suspected pancreatitis or carcinoma of the pancreas. Two different methods were developed to demonstrate the mutations. With the aid of one of these methods, enrichment PCR with analysis of the restriction fragment length (FL), mutations on codon 12 of the Ki-ras gene were demonstrated in unstimulated pancreatic secretions of 29 of 33 patients with pancreatic carcinoma. All eleven fine-needle biopsies that had been cytologically examined showed the tumour-specific mutation. After direct sequencing of enrichment PCR a codon 12 mutation was demonstrated in pancreatic secretion from 21 of 24 patients and with the single strand conformation polymorphism analysis in 17 of 33 patients. In two of these 33 patients two different Ki-ras mutations were discovered. No mutations were found in acute inflammations or stone disease, while in five patients with chronic pancreatitis mutations were demonstrated only in those two patients in whom histological examination had revealed precancerous mucinous hyperplasia. This investigation indicates that codon 12 mutations of the Ki-ras gene, found after PCR in pancreatic secretion and biopsies, constitute a sensitive and specific tumour marker whose clinical value is being assessed. SN - 0012-0472 UR - https://www.unboundmedicine.com/medline/citation/7781522/[Ki_ras_mutation_as_a_molecular_tumor_marker_for_carcinoma_of_the_pancreas]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2008-1055413 DB - PRIME DP - Unbound Medicine ER -